On May 29, 2025 Grit Biotechnology Co., Ltd. ("Grit Bio"), a clinical-stage biotech pioneering novel immunotherapies reported that three abstracts featuring new clinical data from tumor-infiltrating lymphocytes (TIL) therapies will be presented at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) 42nd annual meeting, which is taking place in Chicago, IL from May 30th to June 3rd (Press release, Grit Bio, MAY 29, 2025, View Source [SID1234653494]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Grit Bio will provide the clinical updates of its leading TIL programs, including GT101 – an unmodified TIL therapy in treating recurrent and metastatic cervical cancer, GT201 – an armored TIL product expressing membrane bond IL-15 complex in treating various solid tumors, and GT300 – a CRISPR/Cas-edited dual KO TIL product in treating advanced solid tumors. The details of Grit Bio’s poster presentations are included below. The abstracts were published via the ASCO (Free ASCO Whitepaper) website on May 22, 2025.
Title: GT101 autologous TIL therapy in patients with recurrent and metastatic cervical cancer: A phase 1 study.
Presentation Type: Poster
Time: 9:00 AM-12:00 PM CT, Sunday, June 1st
Poster # 431
Abstract #: 5533
Title: Assessing the Safety and Efficacy of GT201: A First-in-Class Autologous Tumor-Infiltrating Lymphocyte Monotherapy in Advanced Solid Tumors
Presentation Type: Poster
Time: 9:00 AM-12:00 PM CT, Monday, June 2nd
Poster #: 446
Abstract #: 6038
Title: Evaluating the Safety and Efficacy of CRISPR/Cas-Modified Tumor Infiltrating Lymphocytes (GT300) as Monotherapy in Advanced Solid Tumors
Presentation Type: Poster
Time: 9:00 AM-12:00 PM CT, Sunday, June 1st
Poster #: 511
Abstract #: 5613
"We have harnessed cutting-edge technologies, including advanced gene editing tools, to enhance the potency and persistence of our TIL products, enabling the development of multiple differentiated TIL pipelines." said Dr. Yarong Liu, Founder and Chief Executive Officer of Grit Biotechnology. "These therapies have demonstrated promising clinical potential across a wide range of indications. Looking forward, we remain committed to accelerating their clinical advancement and actively seeking global collaborations to bring these transformative therapies to patients worldwide."